Country: Canada
Language: English
Source: Health Canada
LEVETIRACETAM
AURO PHARMA INC
N03AX14
LEVETIRACETAM
750MG
TABLET
LEVETIRACETAM 750MG
ORAL
30/100/250/500
Prescription
MISCELLANEOUS ANTICONVULSANTS
Active ingredient group (AIG) number: 0148843003; AHFS:
APPROVED
2011-10-26
Auro-Levetiracetam Product Monograph Page 1 of 40 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR AURO-LEVETIRACETAM Levetiracetam Tablets Film-coated tablets, 250 mg, 500 mg, and 750 mg, Oral Manufacturer Standard Antiepileptic ATC Code: N03AX14 AURO PHARMA INC. 3700 Steeles Avenue West, Suite # 402 Woodbridge, Ontario, L4L 8K8, Canada Date of Initial Authorization: October 25, 2011 Date of Revision: December 12, 2023 Submission Control Number: 276354 Auro-Levetiracetam Product Monograph Page 2 of 40 RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS, Neurologic 12/2023 7 WARNINGS AND PRECAUTIONS, Psychiatric 12/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ........................................................................................... 2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................... 4 1 INDICATIONS ...................................................................................................................... 4 1.1 Pediatrics .......................................................................................................................... 4 1.2 Geriatrics .......................................................................................................................... 4 2 CONTRAINDICATIONS ......................................................................................................... 4 4 DOSAGE AND ADMINISTRATION ........................................................................................ 4 4.1 Dosing Considerations ...................................................................................................... 4 4.2 Recommended Dose and Dosage Adjustment ................................................................. 4 4.4 Administration ......... Read the complete document